Behzadi, F and Raeisi, M and Nouri Vaskeh, M and Danandeh Mehr, A and Askari, E and Roosta, Y (2021) Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges. Leukemia Research Reports, 15. pp. 1-7.
|
Text
2224.pdf Download (972kB) | Preview |
Abstract
A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interaction between CLL and COVID-19 remains a major challenge. Also, CLL patients have a lower rate of anti-SARS-CoV-2 IgG development. Evidences show the unacceptable therapeutic outcome in these patients. Although the CLL-COVID-19 occurrence is associated with adverse clinical consequences, no general and standard agreement has yet been presented for the management and treatment of this disease
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Chronic lymphocytic leukemia COVID-19 Diagnosis Prevalence Treatment |
| Subjects: | R Medicine > R Medicine (General) |
| Depositing User: | Unnamed user with email gholipour.s@umsu.ac.ir |
| Date Deposited: | 02 Jun 2021 04:38 |
| Last Modified: | 02 Jun 2021 04:38 |
| URI: | http://eprints.umsu.ac.ir/id/eprint/6230 |
Actions (login required)
 |
View Item |
